Please login to the form below
Novartis eyes potential new indication for Cosentyx
Unveils positive late-stage results in axial spondyloarthritis
Acceleron scraps rare muscular dystrophy drug
Clinical profile not strong enough to push into late-stage testing
J&J's Tremfya filed for approval in US for psoriatic arthritis
Seeking share of increasingly competitive psoriasis market
New data backs GeNeuro’s MS drug after Servier exit
Search continues for new development partner
Biogen and Eisai drop Alzheimer’s drug elenbecestat
Latest blow in string of failures for BACE inhibitor category
Aimmune gets FDA panel backing for peanut allergy therapy
Step closer to becoming first approved treatment
FDA fast-tracks AstraZeneca’s Farxiga in heart failure
Races to become first-in-class
Lundbeck bolts on migraine drug via $1.95bn deal to buy Alder
Continues to bulk up its pipeline
AbbVie/Allergan's merger faces public opposition
Advocacy groups and unions in the US express concerns
Q&A: Jessica Pacey
PME interviews the founder and chief executive of newly launched health comms agency, 67health
-
Who's calling the shots in European healthcare?Patients versus Pharma: industry too powerful, and too cosy with EMA, says Yannis Natsis
-
Q&A with Tim CockroftPME interviews the founding director of akt health communications
-
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial Regulatory filings expected in first half of 2020
-
Roche preps filings for Herceptin/Perjeta combinationPotential defence against biosimilar competition
-
IQVIA and partners set up cancer ‘data hub’ to speed up research Seven research centres to be rolled out across UK
-
Roche presents new data in NMOSD, could challenge Alexion's SolirisReduced risk of relapse by 55%
-
J&J’s ponesimiod tops Aubagio in head-to-head MS trialSets up regulatory filings and possible approval next year
-
NICE approves BioMarin’s Brineura after initial setbackFirst treatment for rare disease
-
Gracell reports impressive data with one-day CAR-T for leukaemiaTakes fight to Novartis and Gilead
Latest appointments
-
Life announces two new hiresStrenghtens growing creative department
-
New hires at Bayer, Eisai and Accord HealthcareThe latest movers in pharma
-
New faces at 90TEN, Lucid Group and Porterhouse Latest movers in healthcare comms
-
Senior leadership moves announced at Publicis HealthNew roles will support European operations
-
Lucid Group announces new hires at its creative and digital agency Bluedog Follows group's success at Communiqué 2019
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Events Executive
-
DOE
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....
Latest intelligence
- A roadmap to the successful treatment of Alzheimer’s disease
- Building on past research to learn more about the disease and how to treat it...
- Article: Like, Like, Like: Harnessing the power of social media insights
- ...
- Its Know Your Numbers week
- Do you know yours?...
Quick links
Infographics
